Novartis Licenses Kyorin’s Preclinical Chronic Hives Drug for $55M Upfront

Here are the key details about Novartis licensing Kyorin's preclinical chronic hives candidate:

Novartis is paying $55 million upfront to Kyorin Pharmaceutical for exclusive global rights to KRP-M22314.

KRP-M223 is a preclinical MRGPRX2 antagonist being developed for chronic spontaneous urticaria (CSU) and other allergic/inflammatory diseases involving mast cells14.

The total deal value could reach $832.5 million if all development, approval, and commercialization milestones are met14.

Kyorin retains an option to commercialize KRP-M223 in Japan, while Novartis has an option to co-promote in Japan1.

Novartis will be responsible for global development of KRP-M223, which is currently in the preclinical stage14.

This deal aligns with Novartis' efforts to find a successor to its blockbuster CSU drug Xolair, which faces patent expiration in 20254.

The agreement was announced on March 4, 2025124.

Sources:

1. https://investorshub.advfn.com/boards/readmsg.aspx?messageid=175879900

2. https://endpts.com/novartis-licenses-kyorins-preclinical-chronic-hives-candidate-for-55m-upfront/

4. https://www.fiercebiotech.com/biotech/novartis-inks-preclinical-hives-pact-kyorin-potentially-worth-more-780m